H G Kopp1, S Yildirim, K C Weisel, L Kanz, W Vogel. 1. Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmology, Medical Center II, South West German Cancer Center, Eberhard-Karls-University, Tübingen, Germany. hans-georg.kopp@med.uni-tuebingen.de
Abstract
BACKGROUND: Despite of the introduction of novel treatment modalities for multiple myeloma, high-dose chemotherapy with hematopoietic stem-cell rescue is still considered the standard of care for eligible patients <65 years of age. As we have previously reported, stem-cell grafts regularly contain quantities of plasma cells measurable by flow cytometry. However, the pathogenetic significance of this finding remains unknown. METHODS: Multiple myeloma patients (n = 60) were mobilized with chemotherapy and filgrastim. Peripheral blood stem cell grafts were obtained by standard leukapheresis, and the number of CD38++/CD138+ cells/kg was determined by flow cytometry. Plasma cell contamination above a threshold of 4.5 x 10(5) plasma cells/kg was considered "high", whereas lower quantities of plasma cells or absent plasma cells in the graft were considered "low". RESULTS: Progression-free survival: the median statistical progression-free survival was 33.5 months (range 11-99 months) in the high-contamination group (n = 16) versus 47 months (range 8-148 months) in the low-contamination group (n = 44). This difference turned out not to be statistically significant (P = 0.15). However, the difference was highly significant regarding overall survival with 53 months (range 11-119 months) in the high-contamination group and with 114 months (range 8-158 months) in the low-contamination group (P = 0.012). CONCLUSIONS: Patients with >4.5 x 10(5) plasma cells/kg contaminating the peripheral blood stem cell graft received after high-dose chemotherapy have a significantly reduced overall survival. Whether high contamination of grafts with plasma cells might reflect residual in vivo tumor mass prior to stem cell transplantation and a generally more aggressive behavior of malignant myeloma cells in these patients, or whether reinfused plasma cells contribute to an unfavorable course of disease remains to be determined.
BACKGROUND: Despite of the introduction of novel treatment modalities for multiple myeloma, high-dose chemotherapy with hematopoietic stem-cell rescue is still considered the standard of care for eligible patients <65 years of age. As we have previously reported, stem-cell grafts regularly contain quantities of plasma cells measurable by flow cytometry. However, the pathogenetic significance of this finding remains unknown. METHODS:Multiple myelomapatients (n = 60) were mobilized with chemotherapy and filgrastim. Peripheral blood stem cell grafts were obtained by standard leukapheresis, and the number of CD38++/CD138+ cells/kg was determined by flow cytometry. Plasma cell contamination above a threshold of 4.5 x 10(5) plasma cells/kg was considered "high", whereas lower quantities of plasma cells or absent plasma cells in the graft were considered "low". RESULTS: Progression-free survival: the median statistical progression-free survival was 33.5 months (range 11-99 months) in the high-contamination group (n = 16) versus 47 months (range 8-148 months) in the low-contamination group (n = 44). This difference turned out not to be statistically significant (P = 0.15). However, the difference was highly significant regarding overall survival with 53 months (range 11-119 months) in the high-contamination group and with 114 months (range 8-158 months) in the low-contamination group (P = 0.012). CONCLUSIONS:Patients with >4.5 x 10(5) plasma cells/kg contaminating the peripheral blood stem cell graft received after high-dose chemotherapy have a significantly reduced overall survival. Whether high contamination of grafts with plasma cells might reflect residual in vivo tumor mass prior to stem cell transplantation and a generally more aggressive behavior of malignant myeloma cells in these patients, or whether reinfused plasma cells contribute to an unfavorable course of disease remains to be determined.
Authors: H Einsele; M Bamberg; W Budach; H Schmidberger; C F Hess; B Wörmann; C Meisner; C Straka; H Hebart; L Trümper; N Kröger; A R Zander; S Hegewisch-Becker; D K Hossfeld; H Schmidt; P Müller; G Schlimok; B Hertenstein; D Peest; B Metzner; N Frickhofen; L Kanz; W I Bensinger Journal: Bone Marrow Transplant Date: 2003-09 Impact factor: 5.483
Authors: R M Lemoli; G Martinelli; E Zamagni; M R Motta; S Rizzi; C Terragna; R Rondelli; S Ronconi; A Curti; F Bonifazi; S Tura; M Cavo Journal: Blood Date: 2000-04-01 Impact factor: 22.113
Authors: M Michallet; T Philip; I Philip; H Godinot; C Sebban; G Salles; A Thiebaut; P Biron; F Lopez; P Mazars; N Roubi; T Leemhuis; E Hanania; C Reading; G Fine; K Atkinson; C Juttner; B Coiffier; D Fière; E Archimbaud Journal: Exp Hematol Date: 2000-07 Impact factor: 3.084
Authors: A K Stewart; R Vescio; G Schiller; O Ballester; S Noga; H Rugo; C Freytes; E Stadtmauer; S Tarantolo; F Sahebi; P Stiff; J Meharchard; R Schlossman; R Brown; H Tully; M Benyunes; C Jacobs; R Berenson; M White; J DiPersio; K C Anderson; J Berenson Journal: J Clin Oncol Date: 2001-09-01 Impact factor: 44.544
Authors: Y Gazitt; C C Reading; R Hoffman; A Wickrema; D H Vesole; S Jagannath; J Condino; B Lee; B Barlogie; G Tricot Journal: Blood Date: 1995-07-01 Impact factor: 22.113
Authors: G Schiller; R Vescio; C Freytes; G Spitzer; F Sahebi; M Lee; C H Wu; J Cao; J C Lee; C H Hong Journal: Blood Date: 1995-07-01 Impact factor: 22.113
Authors: M Mohty; K Hübel; N Kröger; M Aljurf; J Apperley; G W Basak; A Bazarbachi; K Douglas; I Gabriel; L Garderet; C Geraldes; O Jaksic; M W Kattan; Z Koristek; F Lanza; R M Lemoli; L Mendeleeva; G Mikala; N Mikhailova; A Nagler; H C Schouten; D Selleslag; S Suciu; A Sureda; N Worel; P Wuchter; C Chabannon; R F Duarte Journal: Bone Marrow Transplant Date: 2014-03-31 Impact factor: 5.483
Authors: Elisabet E Manasanch; Dalia A Salem; Constance M Yuan; Nishant Tageja; Manisha Bhutani; Mary Kwok; Dickran Kazandjian; George Carter; Seth M Steinberg; Diamond Zuchlinski; Marcia Mulquin; Katherine Calvo; Irina Maric; Mark Roschewski; Neha Korde; Raul Braylan; Ola Landgren; Maryalice Stetler-Stevenson Journal: Leuk Lymphoma Date: 2014-10-30
Authors: S Wuillème; A Lok; N Robillard; P Dupuis; V Stocco; H Migné; A Dusquesne; C Touzeau; M Tiab; M C Béné; P Moreau Journal: Bone Marrow Transplant Date: 2016-04-04 Impact factor: 5.483
Authors: Tarek H Mouhieddine; Adam S Sperling; Robert Redd; Jihye Park; Matthew Leventhal; Christopher J Gibson; Salomon Manier; Amin H Nassar; Marzia Capelletti; Daisy Huynh; Mark Bustoros; Romanos Sklavenitis-Pistofidis; Sabrin Tahri; Kalvis Hornburg; Henry Dumke; Muhieddine M Itani; Cody J Boehner; Chia-Jen Liu; Saud H AlDubayan; Brendan Reardon; Eliezer M Van Allen; Jonathan J Keats; Chip Stewart; Shaadi Mehr; Daniel Auclair; Robert L Schlossman; Nikhil C Munshi; Kenneth C Anderson; David P Steensma; Jacob P Laubach; Paul G Richardson; Jerome Ritz; Benjamin L Ebert; Robert J Soiffer; Lorenzo Trippa; Gad Getz; Donna S Neuberg; Irene M Ghobrial Journal: Nat Commun Date: 2020-06-12 Impact factor: 14.919
Authors: Malte Roerden; Stefan Wirths; Martin Sökler; Wolfgang A Bethge; Wichard Vogel; Juliane S Walz Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639